home / stock / slgl / slgl news

SLGL News and Press, Sol-Gel Technologies Ltd.

Stock Information
Company Name: Sol-Gel Technologies Ltd.
Stock Symbol: SLGL
Market: NASDAQ
Website: sol-gel.com
Menu
SLGL SLGL Quote SLGL Short SLGL News SLGL Articles SLGL Message Board
Get SLGL Alerts

News, Short Squeeze, Breakout and More Instantly...
SLGL - US Companies Moving the Markets, Evening edition
Thu, Jul 25, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
SLGL - Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved larg...

SLGL - Sol-Gel Technologies announces CEO Seri-Levy to step down; promotes Eyal Ben-Or as CFO

2024-07-15 07:31:03 ET More on Sol-Gel Technologies Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For...

SLGL - Sol-Gel Technologies Announces Management Realignment

NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
SLGL - Sol-Gel Technologies gets non-compliance notice from Nasdaq

2024-05-28 07:16:25 ET More on Sol-Gel Technologies Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M Read the full article on Seeking Alpha For further details see: Sol-Gel Technologies gets non-compliance notice from Na...

SLGL - Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...

SLGL - SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024

2024-05-20 13:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sol-Gel Technologies (NASDAQ: SLGL ) just reported results for the first quarter of 2024. Sol-Gel Technologies reported earnings per share of -23 cents. This was below the...
SLGL - Sol-Gel Technologies GAAP EPS of -$0.23 misses by $0.08, revenue of $0.47M misses by $0.83M

2024-05-20 09:42:03 ET More on Sol-Gel Technologies Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Finan...

SLGL - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO ® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $ 1 1...

SLGL - Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal

2024-05-20 01:30:00 ET Summary Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments. Zai Lab reported China’s NMPA approved Augtyro ...
Next 10